{"id":"bg00002-natalizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Progressive multifocal leukoencephalopathy (PML)"},{"rate":"approximately 20-30%","effect":"Infusion reactions"},{"rate":"approximately 10-15%","effect":"Headache"},{"rate":"approximately 10-15%","effect":"Fatigue"},{"rate":"approximately 5-10%","effect":"Arthralgia"},{"rate":"approximately 5-10%","effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to α4β1 integrin, natalizumab inhibits the adhesion and transmigration of lymphocytes across the blood-brain barrier and into inflamed tissues. This reduces the infiltration of immune cells into the brain and spinal cord, thereby decreasing inflammation and demyelination in multiple sclerosis. The drug effectively reduces relapse rates and slows disease progression in relapsing-remitting MS.","oneSentence":"Natalizumab is a monoclonal antibody that blocks the α4β1 integrin on immune cells, preventing their migration across the blood-brain barrier into the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:54.021Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT05265728","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis","status":"TERMINATED","sponsor":"Biogen","startDate":"2022-04-26","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":21},{"nctId":"NCT05688436","phase":"","title":"A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies","status":"RECRUITING","sponsor":"Biogen","startDate":"2021-09-24","conditions":"Multiple Sclerosis","enrollment":1178},{"nctId":"NCT05658497","phase":"","title":"Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)","status":"RECRUITING","sponsor":"Biogen","startDate":"2023-10-27","conditions":"Multiple Sclerosis","enrollment":908},{"nctId":"NCT05532163","phase":"PHASE4","title":"A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)","status":"TERMINATED","sponsor":"Biogen","startDate":"2023-01-23","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1},{"nctId":"NCT03689972","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration","status":"COMPLETED","sponsor":"Biogen","startDate":"2018-11-27","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":585},{"nctId":"NCT00707512","phase":"","title":"CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring","status":"TERMINATED","sponsor":"Biogen","startDate":"2008-06-30","conditions":"Crohn's Disease","enrollment":87},{"nctId":"NCT02142192","phase":"PHASE2","title":"Natalizumab Subcutaneous Immunogenicity and Safety Study","status":"TERMINATED","sponsor":"Biogen","startDate":"2014-12-01","conditions":"Relapsing Multiple Sclerosis","enrollment":2},{"nctId":"NCT00493298","phase":"","title":"Tysabri Observational Program","status":"COMPLETED","sponsor":"Biogen","startDate":"2007-06-29","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":6620},{"nctId":"NCT03399981","phase":"","title":"Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-06-01","conditions":"Progressive Multifocal Leukoencephalopathy","enrollment":80327},{"nctId":"NCT04832399","phase":"","title":"Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-11-12","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":60},{"nctId":"NCT03283371","phase":"PHASE2","title":"Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy","status":"COMPLETED","sponsor":"Biogen","startDate":"2018-03-20","conditions":"Epilepsy, Focal Seizures, Partial Seizures","enrollment":67},{"nctId":"NCT01485003","phase":"","title":"Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2012-02-07","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":231},{"nctId":"NCT02730455","phase":"PHASE2","title":"Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-07-18","conditions":"Acute Ischemic Stroke","enrollment":277},{"nctId":"NCT02677077","phase":"","title":"Clinical Disease Activity With Long Term Natalizumab Treatment","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-12-31","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":277},{"nctId":"NCT00884481","phase":"","title":"Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-03-23","conditions":"Relapsing-Remitting Multiple Sclerosis, Fatigue","enrollment":195},{"nctId":"NCT02386566","phase":"","title":"Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-03-20","conditions":"Multiple Sclerosis","enrollment":48},{"nctId":"NCT01943526","phase":"","title":"Ireland Natalizumab (TYSABRI) Observational Program","status":"COMPLETED","sponsor":"Biogen","startDate":"2011-11-30","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":191},{"nctId":"NCT01416181","phase":"PHASE3","title":"A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis","status":"TERMINATED","sponsor":"Biogen","startDate":"2011-09-13","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":889},{"nctId":"NCT02342704","phase":"PHASE4","title":"Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants","status":"TERMINATED","sponsor":"Biogen","startDate":"2014-11-30","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":111},{"nctId":"NCT02241785","phase":"PHASE4","title":"Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies","status":"TERMINATED","sponsor":"Biogen","startDate":"2014-09-30","conditions":"Relapsing Multiple Sclerosis","enrollment":47},{"nctId":"NCT00306592","phase":"PHASE3","title":"Natalizumab Re-Initiation of Dosing","status":"COMPLETED","sponsor":"Biogen","startDate":"2006-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":404},{"nctId":"NCT00871780","phase":"PHASE4","title":"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-08","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":224},{"nctId":"NCT00536120","phase":"PHASE4","title":"The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2008-01","conditions":"Multiple Sclerosis","enrollment":60},{"nctId":"NCT01070836","phase":"","title":"JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-03","conditions":"Relapsing Multiple Sclerosis","enrollment":35895},{"nctId":"NCT00297232","phase":"PHASE3","title":"Natalizumab (Tysabri) Re-Initiation of Dosing","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-03","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":1094},{"nctId":"NCT01955707","phase":"PHASE2","title":"Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-01","conditions":"Acute Ischemic Stroke","enrollment":161},{"nctId":"NCT01884935","phase":"PHASE1","title":"PK and PD Study of Natalizumab in Pediatric Subjects With RRMS","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-07","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":13},{"nctId":"NCT02159573","phase":"","title":"Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-07","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":530},{"nctId":"NCT01416155","phase":"PHASE2","title":"Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-10","conditions":"Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis","enrollment":97},{"nctId":"NCT02137109","phase":"","title":"Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-03","conditions":"Multiple Sclerosis","enrollment":400},{"nctId":"NCT01405820","phase":"PHASE2","title":"Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2011-08","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":290},{"nctId":"NCT00744679","phase":"PHASE4","title":"A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State","status":"COMPLETED","sponsor":"Biogen","startDate":"2008-11","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT01440101","phase":"PHASE2, PHASE3","title":"Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-11","conditions":"Multiple Sclerosis","enrollment":106},{"nctId":"NCT00675428","phase":"PHASE1, PHASE2","title":"Study of Natalizumab in Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Biogen","startDate":"2008-09","conditions":"Multiple Myeloma","enrollment":6},{"nctId":"NCT00559702","phase":"PHASE1","title":"Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2007-10","conditions":"Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":76},{"nctId":"NCT01058005","phase":"PHASE3","title":"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis","status":"TERMINATED","sponsor":"Biogen","startDate":"2010-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":84},{"nctId":"NCT02142205","phase":"PHASE4","title":"Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2012-05","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":100},{"nctId":"NCT00516893","phase":"PHASE2","title":"Natalizumab High Titer Immunogenicity and Safety","status":"COMPLETED","sponsor":"Biogen","startDate":"2006-10","conditions":"Multiple Sclerosis","enrollment":113}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tysabri","Tysabri®"],"phase":"marketed","status":"active","brandName":"BG00002 (natalizumab)","genericName":"BG00002 (natalizumab)","companyName":"Biogen","companyId":"biogen","modality":"Biologic","firstApprovalDate":"","aiSummary":"Natalizumab is a monoclonal antibody that blocks the α4β1 integrin on immune cells, preventing their migration across the blood-brain barrier into the central nervous system. Used for Relapsing-remitting multiple sclerosis, Crohn's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}